$MGRX

MANGOCEUTICALS, INC.

CIK:0001938046|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues
Revenues	$ 68,757	$ 168,109	$ 136,621	$ 277,415
Cost of revenues	10,437	18,815	18,655	43,552
Cost of revenues - related party	14,105	59,346	44,750	81,851
Gross profit	44,215	89,948	73,216	152,012
Operating expenses
General and administrative expenses	256,095	1,245,360	1,322,668	2,787,804
Salary and benefits	427,298	628,343	774,158	1,254,941
Advertising and marketing	301,445	258,295	395,518	540,027
Investor relations		106,000		1,525,000
Stock based compensation	92,417	3,120,445	1,740,238	4,165,924
Total operating expenses	1,077,255	5,358,443	4,232,582	10,273,696
Loss from operations	(1,033,040)	(5,268,495)	(4,159,366)	(10,121,684)
Other (income) expense
Interest expense		21,700		8,000
Interest expense - amortization of intangible assets	279,891		556,706
Loss from settlement		125,625		125,625
Total other expense	279,891	147,325	556,706	133,625
Loss before income taxes	(1,312,931)	(5,415,820)	(4,716,072)	(10,255,309)
Income taxes
Net loss	(1,312,931)	(5,415,820)	(4,716,072)	(10,255,309)
Net income (loss) attributed to non-controlling interest	(278)	(2)	(269)	(100)
Net loss attributed to Mangoceuticals, Inc.	$ (1,312,653)	$ (5,415,818)	$ (4,715,803)	$ (10,255,209)
Basic and diluted loss per share
Diluted loss per share	$ (0.09)	$ (0.57)	$ (0.32)	$ (1.49)
Basic loss per share	$ (0.09)	$ (0.57)	$ (0.32)	$ (1.49)
Weighted average number of shares outstanding
Basic	17,119,619	9,983,376	16,802,376	7,282,955
Diluted	17,119,619	9,983,376	16,802,376	7,282,955
Preferred stock dividend requirements	$ 294,000	$ 294,000	$ 588,000	$ 588,000
Net loss attributed to Mangoceuticals, Inc. common stockholders	$ (1,606,653)	$ (5,709,818)	$ (5,303,803)	$ (10,843,209)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,716,072)	$ (10,255,309)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	502	502
Issuance of common stock for services	669,107	5,113,591
Options vested for stock-based compensation	1,102,531	101,958
Amortization of intangible assets	556,706	554,913
Amortization of license agreement	29,206	695,811
Operating lease right of use asset	28,615	31,823
(Increase) decrease in operating assets:
Due from related party	20,056
Deposits	16,942
(Decrease) increase in operating liabilities:
Accounts payable and accrued liabilities	473,053	430,494
Accrued liabilities - related parties	6,000	30,000
Deposit/contract liability	275,000
Operating lease right of use liabilities	(28,616)	(34,845)
Payroll tax liabilities	(2,787)	2,973
Other liabilities	(9,191)	(212,316)
Other liabilities -related parties		9,175
NET CASH USED IN OPERATING ACTIVITIES	(1,571,849)	(3,531,230)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings on notes payable		500,000
Proceeds from borrowings on notes payable - related parties	44,944	100,000
Proceeds from sales of common stock	272,000	1,085,785
Proceeds from sales of series B convertible preferred stock		100,000
Proceeds from exercise of warrants		630,000
Collection of subscriptions receivable		1,150,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	316,944	3,565,785
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
End of period	(1,254,905)	34,555
CASH AND CASH EQUIVALENTS:
Beginning of period	1,486,338	58,653
Effects of currency translation on cash and cash equivalents	(2,745)	7,811
End of period	228,688	101,019
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock for master distribution agreement		6,713,000
Series C Convertible Preferred accrued dividend	588,000	588,000
Issuance of common stock for settlement of note payable		500,000
Issuance of common stock for settlement of note payable - related parties		150,000
Issuance of common stock for conversion of Series B Convertible Preferred		162
Issuance of common stock for cashless warrant exercise		23
Issuance of common stock for subscriptions receivable		224,569
Related Party [Member]
(Increase) decrease in operating assets:
Prepaid expenses	120
Nonrelated Party [Member]
(Increase) decrease in operating assets:
Prepaid expenses	$ 6,979

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and cash equivalents	$ 228,688	$ 1,486,338
Deposits	16,957	33,899
Due from related party		20,056
TOTAL CURRENT ASSETS	245,687	1,547,434
NON-CURRENT ASSETS
Property and equipment, net of accumulated depreciation of $3,770 and $3,268	1,292	1,794
Right of use - asset	279,246	307,861
Intangible assets - acquired patents and license, net of amortization	13,646,570	14,232,484
TOTAL NON-CURRENT ASSETS	13,927,108	14,542,139
TOTAL ASSETS	14,172,795	16,089,573
CURRENT LIABILITIES
Accounts payable and accrued liabilities	889,733	416,682
Payroll tax liabilities	6,634	9,421
Deposit/contract liability	275,000
Operating lease liability - current	28,301	307,823
Accrued liabilities - related parties	6,000
Notes payable - related parties	44,944
TOTAL CURRENT LIABILITIES	1,398,063	890,568
LONG-TERM LIABILITIES
Operating lease liability - net of current portion	250,906
TOTAL LONG-TERM LIABILITIES	250,906
TOTAL LIABILITIES	1,648,969	890,568
COMMITMENTS AND CONTINGENCIES (SEE NOTE 7)
STOCKHOLDERS’ EQUITY
Common stock (par value $0.0001), 200,000,000 shares authorized, of which 18,017,421 and 15,888,795 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	1,803	1,589
Stock warrants	324,288	324,288
Additional paid in capital	57,568,236	55,524,812
Accumulated deficit	(45,363,283)	(40,647,480)
Accumulated other comprehensive loss	(5,198)	(2,760)
TOTAL STOCKHOLDERS’ EQUITY	12,525,944	15,200,547
Non-controlling interest	(2,118)	(1,542)
TOTAL STOCKHOLDERS’ EQUITY	12,523,826	15,199,005
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	14,172,795	16,089,573
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock, value
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock, value	98	98
Nonrelated Party [Member]
CURRENT ASSETS
Prepaid expenses	42	7,021
Related Party [Member]
CURRENT ASSETS
Prepaid expenses		120
Patent Purchase Payable [Member]
CURRENT LIABILITIES
Other liabilities	$ 147,451	$ 156,642